Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study

Date

03 Mar 2020

Session

Proffered Papers 2: Individual targets

Presenters

Antoine Hollebecque

Citation

Annals of Oncology (2020) 31 (suppl_1): S8-S10. 10.1016/annonc/annonc82

Authors

A. Hollebecque1, J.S. de Bono2, S. Salvagni3, R. Plummer4, P. Niccoli5, J. Capdevila6, G. Curigliano7, V. Moreno8, F. De Braud9, M. López-Brea10, P. Martin-Romano11, E. Baudin1, M. Arias12, J. De Alvaro12, J. Parra-Palau12, T. Sánchez-Pérez12, I. Aronchik13, E. Filvaroff13, M. Lamba13, Z. Nikolova12

Author affiliations

  • 1 Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 The Institute of Cancer Research and Royal Marsden, SW7 3RP - London/GB
  • 3 Policlinico S. Orsola Malpighi University Hospital, 40138 - Bologna/IT
  • 4 Translational and Clinical Research Institute, Newcastle University, DN - Newcastle/GB
  • 5 Institut Paoli-Calmettes, Marseille/FR
  • 6 Vall d´Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona/ES
  • 7 Istituto Europeo di Oncologia, IRCCS, University of Milano, 20141 - Milan/IT
  • 8 START Madrid-FJD, Hospital Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 9 Istituto Nazionale dei Tumori, Milan/IT
  • 10 H.U. Marqués de Valdecilla, Santander/ES
  • 11 Institut Gustave Roussy, Villejuif/FR
  • 12 Celgene, A Bristol-Myers Squibb Company, Summit/US
  • 13 Bristol-Myers Squibb, Summit/US
More

Resources

CC-90011 is an oral, potent, selective, and reversible inhibitor of lysine-specific demethylase 1A. Prior results from the CC-900011-ST-001 study showed that CC-90011 was well tolerated and had promising preliminary antitumor activity in pts with advanced unresectable STs and R/R NHL. Here we present updated results with longer follow-up and additional pts.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings